Second Circuit revives competition suit against Takeda

13-02-2017

The US Court of Appeals for the Second Circuit has partly revived a competition case against Takeda that accuses the company of delaying generic versions of its diabetes drug Actos (pioglitazone).


US Court of Appeals for the Second Circuit, Takeda, Teva, Actos, anti-competition, generics, Food and Drug Administration, FDA, class action,

LSIPR